| Identification | Back Directory | [Name]
Bromotetrandrine | [CAS]
62067-29-2 | [Synonyms]
W198
W-198
BrTet
W 198
Bromotetrandrine
5-Bromotetrandrine
16H-1,24:6,9-Dietheno-11,15-metheno-2H-pyrido[2',3':17,18][1,11]dioxacycloeicosino[2,3,4-ij]isoquinoline, 20-bromo-3,4,4a,5,16a,17,18,19-octahydro-12,21,22,26-tetramethoxy-4,17-dimethyl-, (4aS,16aS)- | [Molecular Formula]
C38H41BrN2O6 | [MOL File]
62067-29-2.mol | [Molecular Weight]
701.66 |
| Hazard Information | Back Directory | [Uses]
Bromotetrandrine is a potent inhibitor of P-glycoprotein (P-gp)-mediated multidrug resistance (MDR). Bromotetrandrine shows significant MDR reversal activity in vitro and in vivo, which may be related to the inhibition of P-gp overexpression and the increase in intracellular accumulation of anticancer agents. Bromotetrandrine is a brominated derivative of tetrandrine, which is promising for MDR modulator for tumor assessment[1][2]. | [References]
[1] Zheng L, et al. Pharmacokinetics and safety of bromotetrandrine (BrTet, W198) after single-dose intravenous administration in healthy Chinese volunteers. J Clin Pharm Ther. 2010 Feb;35(1):113-9. DOI:10.1111/j.1365-2710.2009.01075.x
[2] Jin J, et al. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine. Cancer Chemother Pharmacol. 2005 Feb;55(2):179-88. DOI:10.1007/s00280-004-0868-0 |
|
|